Clinical Trials

BreastCNSGastrointestinalGenitourinaryGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07523529 2026-04-13

SELECT-2CAR

Phase 1/2 Recruiting

72 enrolled

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Recruiting

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT06072612 2026-04-07

BRIA-ABC

Phase 3 Recruiting

404 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT03328026 2026-03-27

Combination Study of SV-BR-1-GM With Retifanlimab

Phase 1/2 Completed

36 enrolled

Breast Neoplasms

NCT07486089 2026-03-20

DUAL-NK-BC

Phase 1/2 Recruiting

60 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

372 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT03036488 2025-10-29

MK-3475-522

1,174 enrolled 2 FDA

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05678205 2025-07-30

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Phase 1/2 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

1,240 enrolled

Breast Neoplasms

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT06341647 2025-01-24

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Phase 1 Withdrawn

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

521 enrolled 17 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Neoplasms

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1 Completed

12 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03013504 2024-11-06

TROIKA

503 enrolled

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1 Completed

59 enrolled

Breast Neoplasms, Neutropenia

NCT03498716 2024-08-21

IMpassion030

Phase 3 Terminated

2,199 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 3 FDA

Breast Neoplasms

NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase 1/2 Terminated

3 enrolled 9 charts

Advanced Triple Negative Breast Cancer

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Phase 2 Recruiting

79 enrolled

Breast Neoplasms

NCT05207514 2024-05-17

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Phase 3 Terminated

26 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

257 enrolled

Breast Neoplasms

NCT06227117 2024-03-19

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Phase 2 Recruiting

120 enrolled

Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Completed

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03752723 2024-03-05

KEYNOTE-899

Phase 1/2 Completed

84 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Phase 2 Completed

126 enrolled 16 charts

BreastDermatologicGastrointestinalGynecologicSarcomaThoracic

Breast Neoplasms

NCT04282044 2024-02-08

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Phase 1 Recruiting

60 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Osteosarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

BreastGynecologicPlasma cellThoracic

16 enrolled

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

BreastGenitourinaryGynecologic

10 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03197935 2023-10-26

IMpassion031

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastDermatologicGenitourinaryThoracic

12 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

16 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors